N. J. Robert

742 total citations
17 papers, 568 citations indexed

About

N. J. Robert is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, N. J. Robert has authored 17 papers receiving a total of 568 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in N. J. Robert's work include Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (7 papers) and HER2/EGFR in Cancer Research (7 papers). N. J. Robert is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (7 papers) and HER2/EGFR in Cancer Research (7 papers). N. J. Robert collaborates with scholars based in United States, Ireland and Canada. N. J. Robert's co-authors include Joseph T. Ferrucci, W P Harbin, Michael B. Atkins, J W Mier, Katie M. O’Brien, Eric K. Rowinsky, Herbert Tilg, George W. Sledge, Gloria Vachino and Daniel D. Karp and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Radiology.

In The Last Decade

N. J. Robert

17 papers receiving 543 citations

Peers

N. J. Robert

ONCOL

HEPAT

EPIDE

IMMUN

RNMI

Horacio Oliva Spain

D. Canioni France

Silvia Martina Ferrari Italy

Adarsh Joshi United States

Lau Wy Hong Kong

Yukio KUSUMOTO Japan

Tomoko Ohtsu Japan

Robert Rosler United States

Kazuhiko Nakagami Japan

Clare M. Morland United Kingdom

Horacio Oliva Spain

N. J. Robert

148 ×0.6

ONCOL

247 ×1.3

HEPAT

246 ×1.3

EPIDE

47 ×0.6

IMMUN

15 ×0.2

RNMI

Citations per year, relative to N. J. Robert N. J. Robert (= 1×) peers Horacio Oliva

Countries citing papers authored by N. J. Robert

Since Specialization

Citations

This map shows the geographic impact of N. J. Robert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. J. Robert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. J. Robert more than expected).

Fields of papers citing papers by N. J. Robert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. J. Robert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. J. Robert. The network helps show where N. J. Robert may publish in the future.

Co-authorship network of co-authors of N. J. Robert

This figure shows the co-authorship network connecting the top 25 collaborators of N. J. Robert. A scholar is included among the top collaborators of N. J. Robert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. J. Robert. N. J. Robert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Robert, N. J., et al.. (2016). Abstract P4-14-13: Pertuzumab (P) use in first-line HER2-positive metastatic breast cancer (mBC) in US community oncology practices: Treatment patterns and outcomes. Cancer Research. 76(4_Supplement). P4–14. 4 indexed citations

2.

Jones, SE, D Paul, Ruth Oratz, et al.. (2011). PD07-03: Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab (HER TC) in HER2−Positive Early Stage Breast Cancer Patients.. Cancer Research. 71(24_Supplement). PD07–3. 2 indexed citations

3.

Valero, Vicente, DJ Slamon, W. Eiermann, et al.. (2011). Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: A phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH).. Journal of Clinical Oncology. 29(15_suppl). 553–553. 2 indexed citations

4.

Siedentopf, Friederike, Winfried Schoenegg, M. Kaufmann, M. Debled, & N. J. Robert. (2010). Efficacy of capecitabine (C)-based therapy in patients with first-line metastatic breast cancer (MBC) previously treated with adjuvant anthracyclines and taxanes.. Journal of Clinical Oncology. 28(15_suppl). 665–665. 1 indexed citations

5.

Hurvitz, Sara A., David J. Betting, Howard M. Stern, et al.. (2009). Analysis of Fcγ Receptor IIA & IIIA Polymorphisms: Correlation with Outcome in Trastuzumab-Treated HER2/Neu Amplified Early and Metastatic Breast Cancer Patients.. Cancer Research. 69(24_Supplement). 64–64. 8 indexed citations

6.

Danso, Michael, JL Blum, N. J. Robert, et al.. (2008). Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1075–1075. 27 indexed citations

7.

Robert, N. J., Paul Conkling, Kristi McIntyre, et al.. (2008). Results of a phase II study of pemetrexed as first-line chemotherapy for advanced or metastatic breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1073–1073. 2 indexed citations

8.

Robert, N. J., W. Eiermann, Tadeusz Pieńkowski, et al.. (2007). BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of life (QOL) at 36 months follow-up. Journal of Clinical Oncology. 25(18_suppl). 19647–19647. 18 indexed citations

9.

Beveridge, Roy, N. J. Robert, Shyamal D. Desai, & Robert McCormack. (2005). Early assessment of circulating tumor cell results in a community-based practice. Journal of Clinical Oncology. 23(16_suppl). 621–621. 8 indexed citations

10.

Robert, N. J., Brian Leyland‐Jones, Lina Asmar, et al.. (2004). Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. Journal of Clinical Oncology. 22(14_suppl). 573–573. 28 indexed citations

11.

Robert, N. J., Brian Leyland‐Jones, Lina Asmar, et al.. (2004). Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. Journal of Clinical Oncology. 22(14_suppl). 573–573. 12 indexed citations

12.

Sledge, George W., N. J. Robert, J. A. Sparano, et al.. (1995). Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer.. PubMed. 22(3 Suppl 6). 105–8. 34 indexed citations

13.

Sledge, George W., N. J. Robert, J. A. Sparano, et al.. (1994). Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.. PubMed. 21(5 Suppl 8). 15–8. 43 indexed citations

14.

Robert, N. J., et al.. (1993). Phase I trial of adriamycin (A) + taxol (T) in metastatic breast cancer (MBC). European Journal of Cancer. 29. S81–S81. 7 indexed citations

15.

Atkins, Michael B., Gloria Vachino, Herbert Tilg, et al.. (1992). Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.. Journal of Clinical Oncology. 10(11). 1802–1809. 65 indexed citations

16.

Mier, J W, et al.. (1991). Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study.. Journal of Clinical Oncology. 9(10). 1821–1830. 70 indexed citations

17.

Harbin, W P, N. J. Robert, & Joseph T. Ferrucci. (1980). Diagnosis of cirrhosis based on regional changes in hepatic morphology: a radiological and pathological analysis.. Radiology. 135(2). 273–283. 237 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact